Aon’s latest deep dive into commercial health-claims data is giving employers a new kind of headache: the good-news, bad-news kind. The consulting giant says that sustained use of GLP-1 therapies can slow long-term medical-cost growth for employer plans while delivering sizable clinical benefits, especially for women. The catch is familiar to every HR and benefits leader in the country: pay steep pharmacy bills today or risk even bigger medical, disability, and productivity costs tomorrow.
What Aon found
In its phase-two study, Aon looked at de-identified medical and pharmacy claims for roughly 192,000 people who started GLP-1 therapy and compared them with matched non-users, pulling from a dataset that covers tens of millions of commercially insured lives. According to the company, female GLP-1 users showed about a 50 percent lower incidence of ovarian cancer and a 47 percent reduction in hospitalizations for major cardiovascular events. Patients who hit at least 80 percent adherence to their medication saw the biggest slowdown in medical-cost growth, Aon said in a press release, according to Aon.
Costs and employer calculus
On the balance sheet, though, the pain is immediate. Coverage and rising utilization have pushed GLP-1 spending sharply higher, and benefits teams are staring at big pharmacy liabilities that hit this year, not in some distant future. Early industry coverage has also pointed out that many members see double-digit increases in medical and pharmacy claims in the first 12 months on therapy before cost growth starts to moderate, which makes return-on-investment math a lot less tidy. As reported by HR Brew, plan sponsors are trying to decide whether the short-term hit is worth the chance at lower hospital and chronic-disease costs down the line.
What employers should consider
“The real impact comes when employers consider not just coverage, but also how these medications are used, supported and sustained over time,” Farheen Dam, Aon’s North America health solutions leader, said in the company release. Aon is urging employers to pair GLP-1 access with adherence support and broader wellbeing programs so they have a better shot at capturing the clinical gains and translating them into long-term savings. The firm’s core message, program design matters at least as much as deciding whether to open up coverage.
Even with that guidance, plenty of employers are keeping GLP-1 benefits on a short leash. Surveys and benefits research show that coverage for GLP-1s specifically for weight loss is anything but uniform, with large employers reporting a mix of prior-authorization requirements and eligibility limits, according to KFF and a Mercer employer survey. The patchwork approach means some plan sponsors are treating GLP-1s like a long-term investment, while others see them as an expense that could blow up the budget.
The new analysis has already drawn interest in the business press, including coverage by Crain's Chicago Business, and the findings are likely to show up in upcoming benefits-planning debates as pricing trends, adherence data and policy rules evolve. For HR teams, the real-world decision will come down to how programs are designed, what manufacturers charge, and whether the clinical signals Aon is flagging are confirmed by independent research. Those variables will decide whether GLP-1 coverage becomes a long-term win or a very costly experiment.
